Johnson & Johnson has reportedly stopped the production of its single-dose COVID-19 vaccine, signaling that the company may cut back on its overall production of the vaccine.

The news: The New York Times reports that Johnson & Johnson quietly shut down production at a plant in the Netherlands, which was the only location that was creating usable doses of the J&J COVID-19 vaccine.

Yes, but: “The facility, in the Dutch city of Leiden, has instead been making an experimental but potentially more profitable vaccine to protect against an unrelated virus,” per The New York Times

  • The halt in production will last temporarily, per The New York Times.
  • It’s unclear if the shutdown will impact overall J&J vaccine supplies because there are stockpiles of the vaccine available.
Related
Does the J&J COVID-19 vaccine stop the omicron variant?
CDC experts recommend these two COVID-19 vaccines over others

The other side: J&J did not confirm the planet closure, but told CBS News that ”we currently have millions of doses of our COVID-19 vaccine in inventory” and “we continue to fulfill our contractual obligations ... (to) the African Union.”

View Comments

One thing to watch: In October 2021, Johnson & Johnson said it would commit about 50 million vaccines to COVAX, the global initiative to give vaccines throughout the world, according to The Hill.

  • It’s unclear if the production shutdown would impact the distribution of those vaccines.
Join the Conversation
Looking for comments?
Find comments in their new home! Click the buttons at the top or within the article to view them — or use the button below for quick access.